Abstract | OBJECTIVE: DESIGN: Prospective study. ANIMALS: 38 dogs < 24 months old with severe SAS (peak systolic pressure gradient > or = 80 mm Hg). PROCEDURE: 10 dogs underwent balloon valvuloplasty and were reexamined 6 weeks later to determine the feasibility of the procedure. The remaining 28 dogs were randomly assigned to undergo balloon valvuloplasty (n = 15) or to be treated with atenolol long term (13) and were reexamined annually for 9 years or until the time of death. RESULTS: For the first 10 dogs, mean pressure gradient 6 weeks after balloon valvuloplasty (mean +/- SD, 119 +/- 32.6 mm Hg) was significantly decreased, compared with mean baseline pressure gradient (167 +/- 40.1 mm Hg). Median survival time for dogs that underwent balloon valvuloplasty (55 months) was not significantly different from median survival time for dogs treated with atenolol (56 months). CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that balloon valvuloplasty can result in a significant decrease in the peak systolic pressure gradient in dogs with severe SAS, at least for the short term. No clear benefit in survival times was seen for dogs that underwent balloon valvuloplasty versus dogs that were treated with atenolol.
|
Authors | Kathryn M Meurs, Linda B Lehmkuhl, John D Bonagura |
Journal | Journal of the American Veterinary Medical Association
(J Am Vet Med Assoc)
Vol. 227
Issue 3
Pg. 420-4
(Aug 01 2005)
ISSN: 0003-1488 [Print] United States |
PMID | 16121608
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Atenolol
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Animals
- Aortic Stenosis, Subvalvular
(drug therapy, therapy, veterinary)
- Atenolol
(therapeutic use)
- Blood Pressure
(physiology)
- Catheterization
(methods, veterinary)
- Dog Diseases
(drug therapy, therapy)
- Dogs
- Female
- Male
- Prospective Studies
- Survival Analysis
|